MX2022001247A - Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r. - Google Patents
Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.Info
- Publication number
- MX2022001247A MX2022001247A MX2022001247A MX2022001247A MX2022001247A MX 2022001247 A MX2022001247 A MX 2022001247A MX 2022001247 A MX2022001247 A MX 2022001247A MX 2022001247 A MX2022001247 A MX 2022001247A MX 2022001247 A MX2022001247 A MX 2022001247A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- antagonist
- atopic dermatitis
- administering
- treating atopic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proveen métodos para tratar dermatitis atópica moderada a grave o grave en un sujeto pediátrico. En un aspecto, los métodos comprenden administrar al sujeto una o más dosis de un antagonista del receptor de interleucina-4 (IL-4R), tal como un anticuerpo anti-IL-4R o un fragmento de unión a antígeno del mismo.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882946P | 2019-08-05 | 2019-08-05 | |
| US201962940108P | 2019-11-25 | 2019-11-25 | |
| US202062985715P | 2020-03-05 | 2020-03-05 | |
| US202063024467P | 2020-05-13 | 2020-05-13 | |
| US202063032408P | 2020-05-29 | 2020-05-29 | |
| PCT/US2020/044960 WO2021026205A1 (en) | 2019-08-05 | 2020-08-05 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001247A true MX2022001247A (es) | 2022-04-25 |
Family
ID=72148241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001247A MX2022001247A (es) | 2019-08-05 | 2020-08-05 | Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210040222A1 (es) |
| EP (1) | EP4010373A1 (es) |
| JP (1) | JP2022543612A (es) |
| KR (1) | KR20220044563A (es) |
| CN (1) | CN114173816A (es) |
| AU (1) | AU2020326713A1 (es) |
| BR (1) | BR112022000377A2 (es) |
| CA (1) | CA3147113A1 (es) |
| IL (1) | IL289930A (es) |
| MX (1) | MX2022001247A (es) |
| SG (1) | SG11202113310UA (es) |
| WO (1) | WO2021026205A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| MX2016011132A (es) | 2014-02-28 | 2016-12-08 | Regeneron Pharma | Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r. |
| MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
| US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| MX2020012064A (es) | 2018-05-13 | 2021-04-13 | Regeneron Pharma | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| CN114173819A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法 |
| WO2024097714A1 (en) | 2022-11-01 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating hand and foot dermatitis by administering an il-4r antagonist |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001272925A1 (en) | 2000-05-26 | 2001-12-11 | Immunex Corporation | Use of interleukin-4 antagonists and compositions thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2543982C (en) | 2003-11-07 | 2013-01-08 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| PL2769992T3 (pl) | 2006-10-02 | 2021-08-02 | Regeneron Pharmaceuticals, Inc. | Przeciwciała ludzkie o wysokim powinowactwie względem ludzkiego receptora IL-4 |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| EA034617B1 (ru) | 2010-10-06 | 2020-02-27 | Ридженерон Фармасьютикалз, Инк. | Дозированная форма жидкой фармацевтической композиции, содержащей антитела к рецептору интерлейкина-4 (il-4r) |
| NZ731864A (en) | 2012-09-07 | 2022-07-01 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| US10485844B2 (en) * | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
| MX2020012064A (es) * | 2018-05-13 | 2021-04-13 | Regeneron Pharma | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. |
-
2020
- 2020-08-05 WO PCT/US2020/044960 patent/WO2021026205A1/en unknown
- 2020-08-05 SG SG11202113310UA patent/SG11202113310UA/en unknown
- 2020-08-05 AU AU2020326713A patent/AU2020326713A1/en active Pending
- 2020-08-05 US US16/985,708 patent/US20210040222A1/en active Pending
- 2020-08-05 KR KR1020227007522A patent/KR20220044563A/ko active Search and Examination
- 2020-08-05 MX MX2022001247A patent/MX2022001247A/es unknown
- 2020-08-05 CA CA3147113A patent/CA3147113A1/en active Pending
- 2020-08-05 CN CN202080054323.2A patent/CN114173816A/zh active Pending
- 2020-08-05 BR BR112022000377A patent/BR112022000377A2/pt unknown
- 2020-08-05 EP EP20758405.3A patent/EP4010373A1/en active Pending
- 2020-08-05 JP JP2022507355A patent/JP2022543612A/ja active Pending
-
2022
- 2022-01-17 IL IL289930A patent/IL289930A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020326713A1 (en) | 2022-02-17 |
| KR20220044563A (ko) | 2022-04-08 |
| WO2021026205A1 (en) | 2021-02-11 |
| BR112022000377A2 (pt) | 2022-05-10 |
| SG11202113310UA (en) | 2021-12-30 |
| EP4010373A1 (en) | 2022-06-15 |
| CN114173816A (zh) | 2022-03-11 |
| JP2022543612A (ja) | 2022-10-13 |
| US20210040222A1 (en) | 2021-02-11 |
| IL289930A (en) | 2022-03-01 |
| CA3147113A1 (en) | 2021-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001247A (es) | Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r. | |
| MX2022011730A (es) | Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r. | |
| MX2020012064A (es) | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. | |
| EP4344706A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| PH12020500368A1 (en) | B7-h4 antibodies and methods of use thereof | |
| EA201891983A8 (ru) | Комбинированная терапия антителами к cd73 | |
| AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
| AU2014306956B2 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| JO3559B1 (ar) | جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه | |
| MX2016010854A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r. | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| MX2021015309A (es) | Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso. | |
| ZA201707869B (en) | Anti-ntb-a antibodies and related compositions and methods | |
| MY202135A (en) | Uses of neuroactive compounds | |
| NZ737399A (en) | Ccr2 modulators | |
| MX363193B (es) | Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r. | |
| PH12017502237A1 (en) | Nuclear receptor modulators | |
| MX2019003338A (es) | Tratamiento de cefalea en racimos. | |
| MX2021013427A (es) | Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33. | |
| MX2016001195A (es) | Metodos para mejorar sintomas de asma mediante el uso de benralizumab. | |
| MX2023003942A (es) | Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r. | |
| MX2017014396A (es) | Tratamiento de mieloma multiple. | |
| PH12017502126A1 (en) | Novel anti-human ngf antibody fab fragment | |
| MX2019014291A (es) | Metodo de tratamiento. | |
| MX2019011847A (es) | Metodo para tratar un efecto secundario de la terapia de celulas t con receptor de antigeno quimerico (car). |